Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Growth in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 75,842 shares, an increase of 1,602.8% from the December 31st total of 4,454 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 645,779 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 645,779 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Daiichi Sankyo Stock Down 2.0%

Shares of OTCMKTS DSNKY traded down $0.40 during mid-day trading on Tuesday, reaching $19.85. The company had a trading volume of 222,628 shares, compared to its average volume of 350,142. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.60 and a current ratio of 2.31. The company has a market capitalization of $37.60 billion and a price-to-earnings ratio of 18.73. The stock has a fifty day moving average of $22.06 and a two-hundred day moving average of $23.60. Daiichi Sankyo has a 12-month low of $19.71 and a 12-month high of $29.68.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.